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What is new?
• A particularly useful feature of network meta-analysis (NMA) is the ability to rank the effectiveness and safety of each intervention in the model for each outcome.
• There are numerous ways to present the results of a NMA, which can challenge the interpretation by research users. Another challenge is the multitude of results from the NMA, which makes it difficult to present all of the data in a single table or figure in a way that is easy to interpret by the readers.
• We propose the rank-heat plot, a novel and simple graphical approach to improve the presentation of results from the treatment ranking analysis for multiple outcomes.
• The rank-heat plot can be used to quickly recognize what are most likely the best and worst interventions with respect to their effectiveness and/or safety in a single or multiple outcome(s), and can identify treatments that have not been studied with regard to particular outcomes.
• Clinicians can use the rank-heat plot to discuss which agent is optimal across the different outcomes with their patients, guideline developers can use it to inform their recommendations, as can policy makers decide about drug coverage.
Introduction
1
Network meta-analysis (NMA) allows the synthesis of data from a network of 2 randomised controlled trials facilitating the simultaneous comparison of many 3 interventions for managing a specific clinical condition. The advantages of NMA (e.g., 4 ranking multiple competing interventions according to their effectiveness and/or safety [1-5 3] ) have increased its application over the last two decades [4] . However, there are 6 numerous ways to present NMA results [5] [6] [7] [8] [9] , and this variation makes their interpretation 7 difficult for research users [10] . Presentation of NMA results becomes even more 8 challenging when large numbers of interventions and outcomes are included. Since the 9 treatment ranking might vary across different outcomes, it is necessary to include all NMA 10 results to make an informed decision about the 'best' available treatment. Several graphical 11 displays have been suggested to present the ranking results of all competing treatments 12 evaluated in a NMA. Hawkins et al [11] were early proponents of presenting the ranking of 13 treatments in a plot (which we later call the 'bubble plot') showing the probability of each 14 treatment being the most effective, the second most effective, etc. Cipriani et al [12] used 15 rankograms to present the distribution of probabilities of each treatment being ranked at 16 each of the possible positions. Salanti et al [5] developed two alternative ways to 17 graphically depict the treatment ranking to facilitate presentation and interpretation of 18 NMA results, including the stacked bar plots and the cumulative ranking probability plots.
19
The latter authors also suggested the use of the surface under the cumulative ranking 20 (SUCRA) curve as an alternative way to rank the treatments, which was a significant 21 advancement in summarizing the NMA findings [5] . Tan et al [7] have proposed the 22 summary forest plot matrix, displaying the NMA and pairwise meta-analysis treatment 23 effect estimates, the heterogeneity estimates, and the ranking and probability best statistics.
24
The authors suggest that pie and rank charts can be used as complementary methods to the 25 summary forest plot matrix to visually summarize the intervention ranking. An approach to 26 summarize the NMA findings of more than one outcome has previously been presented in 27 rankograms, where types of lines correspond to different outcomes [12] . Two-dimensional 28 scatterplots have also been presented in the literature to depict the ranking of treatments for 29 two different outcomes [6, 13] . However, to the best of our knowledge, there no graphical 30 tools available to summarize the ranking statistics of all studied NMA outcomes in a single 31 plot.
32
The aim of this study is to present a novel and simple graphical approach to 33 improve the presentation of results from the treatment ranking for multiple outcomes in 34 NMA. We also discuss approaches that have been suggested to present treatment ranking.
35
Datasets
36
We use three previously published systematic reviews and NMAs to present [15, 16] , and large (5 outcomes and 30 treatments [17] ) 40 databases with respect to the number of treatments and outcomes studied in NMA. Details 41 of these datasets are provided in Text S1 in Supporting Information.
42
Graphical tools for treatment ranking 43 Different graphical displays have been developed to present the ranking results of 44 all competing treatments included in a network. In this paper, we present the graphical 45 approaches for treatment ranking that have been used in published NMAs [4] . The NMA 46 findings can be summarized using the following statistics: 1) mean/median treatment ranking, 2) probability for each treatment in a NMA being the best (P(best)), and 3) the 
Pie chart
57
A pie chart can graphically depict the treatment ranking in a NMA. The area of the 58 circle in a pie chart is divided into T different parts, with T number of treatments in the 59 network. Each region is proportional to the respective ranking probability. The bigger the 60 segment, the better the ranking of the treatment for that outcome.
61
In Figure S1a we present the probability for each long-acting inhaled agent being 62 the safest for chronic obstructive pulmonary disease (COPD) with respect to arrhythmia.
63
This suggests that salmeterol/fluticasone is most likely the best with 38.98% probability to 64 rank first, whereas formoterol/budesonide is the least likely to rank first (probability=0.58%).
66
Rank chart
67
In the rank chart [7] , the treatments are ordered from greatest to lowest probability 68 of being the best. In Figure S1b we present the treatment order according to P(best) for 69 arrhythmia for the COPD NMA, using a color intensity scheme to highlight what is most 70 likely the best treatment. The colored rank chart uses light grey at the top of the chart with 71 the highest P(best) and dark grey at the bottom of the chart to indicate the lowest P(best).
72
Rankogram
73
A rankogram is a two-way plot that shows the ranking probabilities of a treatment 74 on the y-axis that correspond to each of the T positions presented on the x-axis [12] . For a M A N U S C R I P T
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6 specific treatment and outcome, connecting the probabilities against the rank positions 76 yields a rankogram. The greater the curve bends near the origin, the better the treatment.
77
In Figure S2 , the ranking probabilities are presented for each of the 12 COPD long- position. The greater the area in a bar, the higher the probability of the treatment being at 92 the corresponding rank position [5] .
93
In Figure S3 , we present the ranking probabilities for the 12 long-acting inhaled 94 agents using a stacked bar plot. Salmeterol/fluticasone is most likely the safest treatment,
95
as it yields the largest area in the bar that corresponds to rank 1 with respect to arrhythmia. proportional to the ranking probability, and the number in each circle represents the 105 probability for the corresponding treatment to rank at the specific position.
106 Figure S4 demonstrates the bubble plot for the ranking probabilities of the 12 long-107 acting inhaled treatments for arrhythmia. This plot suggests that salmeterol/fluticasone has 108 a 38.98% probability of being the safest and a 0.21% probability of being the least safe.
109
Similarly, vilanterol/fluticasone has a 3.46% probability of ranking 1 st and a 68.59% 110 probability of ranking 12 th .
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et al. [5] suggest summarizing the ranking probabilities using the SUCRA values
115
(expressed in percentages) that can be calculated from the cumulative ranking curves. The 116 larger the area under the curve, the better the treatment.
117
In Figure S5 , we present the SUCRA values and curves for the 12 long-acting 118 inhaled agents for arrhythmia [17] . These results show that the SUCRA for 119 salmeterol/fluticasone of being the safest for arrhythmia is 74.80%, whereas 120 vilanterol/fluticasone has the least probability of being the best (SUCRA=14.10%).
121
Plots for multiple outcomes
122
There are two graphical tools for multiple outcomes; scatterplots and the rank-heat 123 plot (the new graphical tool we are proposing). A scatterplot can only be used when 124 outcome data is available for the same treatments, whereas the rank-heat plot can be used 125 regardless of whether outcome data are available for all treatments. Both plots can be 126 produced for SUCRAs, P(best), or median/mean rankings.
127
Scatterplot
128
The relative ranking for two outcomes has been presented in two-dimensional 129 scatterplots [6] , which can be extended to three-dimensional plots presenting the treatment 
Rank-heat plot
141
The rank-heat plot is a novel approach for the visual presentation of the treatment findings. Hence, the rank-heat plot could be added to the preferred reporting items for 189 systematic reviews and meta-analysis (PRISMA) guideline extention for NMA [10] . preferences are taken into account) and no numerical summary of all outcomes is provided.
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( Table 1 
Can be produced when different treatments are included in the studied outcomes -- Figure 1 . Rank-heat plots of 8 treatments studied in patients with type 1 diabetes in three different outcomes (a) and 15 serotonin (5-HT 3 ) receptor antagonists for patients undergoing surgery in five outcomes (b). Each sector is colored according to the SUCRA value of the corresponding treatment and outcome. The scale consists of the transformation of three colors red (0%), yellow (50%), and green (100%). In (b) each sector includes also the SUCRA value corresponding to the specific treatment and outcome. Uncolored sectors show that the underlying treatment was not included in the NMA for the particular outcome. 
Text S2
R code for rank-heat plot, along with a help file. Figure S1 . Pie chart and rank chart (b) representing the probability for each treatment being the best in the chronic obstructive pulmonary disease (COPD) arrhythmia network. Figure S7 . Rank-heat plot of 15 serotonin (5-HT 3 ) receptor antagonists for patients undergoing surgery in five outcomes. Each sector is colored according to the SUCRA value of the corresponding treatment and outcome. The scale consists of the transformation of three colors red (0%), yellow (50%), and green (100%), and each color is associated with a different pattern. Uncolored sectors show that the underlying treatment was not included in the NMA for the particular outcome.
Figures
